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Abstract
Glycosylphosphatidylinositol-specific phospholipase D from mammalian serum has been described to be relatively stable
towards the action of proteases in vitro, and it has been speculated that the enzyme may only be active on glycosylphos-
phatidylinositol-anchored substrates after its proteolytic processing in an intracellular compartment following uptake from
body fluids. To test this hypothesis, we studied the possible uptake and intracellular processing of purified glycosylphos-
phatidylinositol-specific phospholipase D into the mouse neuroblastoma cell line N2A. We found that after incubation of
neuroblastoma cells with glycosylphosphatidylinositol-specific phospholipase D at 378C the amount of cell-associated
glycosylphosphatidylinositol-specific phospholipase D activity increased in a concentration- and time-dependent way. A
similar uptake was also observed with 125I-labeled intact and trypsin-treated form of glycosylphosphatidylinositol-specific
phospholipase D. We found that the incorporated radiolabeled proteins were processed intracellularly to distinct low
molecular mass products, and that this process was in part inhibited by the presence of chloroquine during incubation.
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1. Introduction
An increasing number of cell surface proteins is
known to be anchored to cell membranes via glyco-
 . sylphosphatidylinositols GPIs for recent reviews
w x.see 1–3 . Despite the fact that this type of mem-
Abbreviations: AChE, acetylcholinesterase; DMEM, Dul-
becco’s modified Eagle’s medium with L-glutamine; FCS, fetal
calf serum; GPI, glycosylphosphatidylinositol; GPI-PLD, glyco-
sylphosphatidylinositol-specific phospholipase D; GPI-PLC, gly-
cosylphosphatidylinositol-specific phospholipase C; SDS-PAGE,
sodium dodecyl sulfate polyacrylamide gel electrophoresis
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brane attachment of proteins is widely distributed in
nature, information on its biological significance is
only starting to emerge. Possible functions of GPI
anchoring may include apical targeting of GPI-
w xanchored proteins in polarized epithelial cells 4,5 ,
w xsignal transduction via GPI structures 6–8 , potocy-
tosis of GPI-anchored proteins, a clathrin-indepen-
w xdent uptake mechanism for GPI-linked molecules 9 ,
and selective release of GPI-anchored proteins from
membranes by GPI-hydrolyzing phospholipases such
as GPI-specific phospholipases C GPI-PLCs; EC
. 3.1.4.10 and GPI-specific phospholipases D GPI-
.PLDs; EC 3.1.4.50 .
A C-type GPI-hydrolyzing phospholipase was first
described in bloodstream forms of the African try-
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panosome, Trypanosoma brucei reviewed by Car-
w x.rington et al. 10 . Subsequently, GPI-PLC activities
were described in other parasites including Plasmod-
w xium falciparum and Plasmodium chabaudi 11 , as
w xwell as in plants 12 . D-type GPI-hydrolyzing phos-
w xpholipases have been isolated from human 13 and
w xbovine serum 14,15 where they occur in high
amounts. In addition, GPI-PLD activities have been
w xdescribed in other mammalian body fluids 15 , as
w xwell as in bovine brain and liver 16,17 . Interest-
ingly, although the purified enzymes have been found
to efficiently cleave GPI-anchored structures in vitro,
the physiological roles of the GPI-PLCs and GPI-
w xPLDs have remained largely unclear 18 .
It has been reported that purified GPI-PLD from
serum is inactive on membrane-bound substrates and
only hydrolyzes GPI structures in the presence of
w xdetergent 14,16 . On the other hand, a GPI-PLD-like
activity has been proposed to release GPI-anchored
w xproteins from cell surfaces 19–21 , however, the
exact mechanisms leading to GPI hydrolysis were not
elucidated. Additional information on the action of
GPI-PLD in vivo is scarce. Davitz and co-workers
w x22,23 reported a release of GPI-anchored proteins
from HeLa cells and bone marrow stromal cells
through the action of a cell-associated GPI-PLD.
Their results indicated that the site of GPI cleavage
was either in a neutral post Golgi compartment or at
w xthe plasma membrane. In addition, Scallon et al. 24
found that in COS cells co-transfected with placental
alkaline phosphatase and GPI-PLD, the GPI anchor
of alkaline phosphatase was hydrolyzed intra-
cellularly prior to attachment of the protein at the cell
surface.
Purified GPI-PLD is remarkably stable towards
w xproteolytic degradation in vitro 25–27 . Treatment of
purified GPI-PLD with trypsin or cathepsin D re-
sulted in generation of distinct sets of degradation
products without incisively affecting GPI-PLD enzy-
matic activity. A recent study on the subcellular
distribution of GPI-PLD in rat liver revealed that the
w xenzyme is enriched in a lysosomal fraction 28 . It is
therefore conceivable that GPI-PLD may act on GPI
substrates after its uptake from serum and proteolytic
w xprocessing in an intracellular compartment 26 . In an
attempt to obtain information on a possible intra-
cellular site of action of GPI-PLD, we studied the
uptake and the intracellular processing of purified
GPI-PLD into the mouse neuroblastoma cell line
N2A.
2. Materials and methods
2.1. Chemicals
All reagents used were of analytical grade and
 . either from Fluka Buchs, Switzerland , Sigma St
.  .Louis, MO, USA , or Merck Darmstadt, Germany .
Dulbecco’s modified Eagle’s medium with L-gluta-
 . mine DMEM was obtained from Seromed Basel,
.  .Switzerland . Fetal calf serum FCS for DMEM was
 .from Seback Aidenbach, Germany . BACTO tryp-
sine was from DIFCO Laboratories Detroit, MI,
. 125 USA . Na I was from Amersham Buckingham-
.shire, UK , and Bio-Gel P-6 desalting gel from Bio-
 .Rad Glattbrug, Switzerland .
2.2. Biological material
 .Acetylcholinesterase AChE; EC 3.1.1.7 from
bovine erythrocytes and GPI-PLD from bovine serum
w xwere purified as described before 15,29 . The
trypsinized form of GPI-PLD was prepared as de-
w x scribed in 27 . Monoclonal antibody 117-1 purified
.IgG raised against purified, denaturated GPI-PLD1
from bovine serum, was provided by Drs B.
 .Nørgaard-Pederson Copenhagen, Denmark and J.
 .Liao. Horseradish-peroxidase HRP -labeled anti-
 .mouse IgG was from BioRad Hercules, CA, USA ,
 .and fluorescein isothiocyanate FITC -conjugated
anti-mouse immunoglobulins from Dako Glostrup,
.Denmark . The mouse neuroblastoma subclone N2A
American Type Culture Collection, Catalog a CCL
. 131 was a gift from Dr. Monard Friedrich Miescher
.Institute, Basel .
2.3. Inacti˝ation of GPI-PLD in FCS
Mammalian sera are known to contain significant
w xamounts of GPI-PLD 15 . Thus, in order to avoid
interference in the GPI-PLD uptake studies by GPI-
PLD activity from FCS, the serum activity was inac-
tivated as follows. The pH of FCS was increased with
10 M NaOH to 11, and the serum was incubated for 1
h at 378C. Subsequently, the pH was brought back to
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pH 7.2 by addition of concentrated hydrochloric acid.
After this treatment no significant GPI-PLD activity
could be measured, even when FCS was kept for 4
days at 378C.
2.4. Cell cultures
N2A cells were cultured in DMEM supplemented
 .with 10% vrv FCS, 200 000 Url penicillin, 1 grl
glucose and 2.2 grl NaHCO . N2A stock cultures3
were maintained at 378C in a humidified atmosphere
of 80% air and 5% CO in 75 cm2 culture flasks2
from Tanner Plastic Products Schonenwerden,¨
.Switzerland . After washing with 8 ml of phosphate-
buffered saline 30 mM phosphate pH 7.4, 120 mM
.NaCl, 2 grl glucose cells were removed from the
culture flasks with 5 ml trypsin-EDTA buffer 0.025%
 .  .wrv trypsin, 0.02% wrv EDTA in phosphate-
.buffered saline at 378C for 3 min. Trypsin activity
was stopped by addition of 6 ml medium containing
 .10% vrv FCS, and cells were collected by centrifu-
 .gation 250=g and resuspended in DMEM. Cells
were split once a week 1:5 and the medium was
changed twice a week. Serum-free cultures were
grown in QBSF-51 medium from Sigma Buchs,
.Switzerland supplemented with 1 mM cholinechlo-
ride and 2.2 grl NaHCO .3
2.5. Uptake of GPI-PLD by N2A cells
Uptake studies were carried out using confluent
 2.cell monolayers in small 20 cm Falcon cell culture
tissue plates. Four days before uptake, N2A cells
were trypsinized, washed three times with 12 ml
phosphate-buffered saliner75 cm2 flask, and sowed
in 20 cm2 Falcon cell culture tissue plates containing
 .DMEM with 10% vrv GPI-PLD-inactivated FCS.
At the beginning of the uptake, cells were washed
twice with phosphate-buffered saline and shifted to
QBSF-51 medium. To half of the plates purified
GPI-PLD was added. At given time points, cells were
 .washed once with 4 ml 0.9% wrv NaCl and scraped
into 9 ml 0.9% NaCl. After centrifugation the pellet
was washed once with 9 ml 0.9% NaCl, and frozen at
y208C. For GPI-PLD activity measurements cells
were thawed and sonicated in 180 ml 10 mM Tris,
 .pH 7.4, 144 mM NaCl, 0.1 mM CaCl assay buffer .2
The cell suspensions were diluted to a final protein
concentration of 3 mgrml, and aliquots of 5 ml were
used for activity measurements. For radioactivity
measurements, cells were thawed and sonicated in
100 ml 10 mM Tris, pH 7.4, 144 mM NaCl Tris-
.buffered saline containing 2.6 mM EDTA, 2 mM
1,10-phenantroline, 270 mM TLCK, and 200 mM
DFP as protease inhibitors. Aliquots were counted in
a MR 252 automatic gamma counting system from
 .Kontron Instruments Zurich, Switzerland .¨
2.6. Assay for GPI anchor-con˝erting acti˝ity using
AChE as substrate
GPI anchor-hydrolyzing activity was measured us-
ing purified membrane form AChE from bovine ery-
w xthrocytes as substrate 15 . Bovine erythrocyte AChE
has a covalently attached GPI anchor and the conver-
sion of amphiphilic AChE to the soluble form serves
as a measure for GPI-degrading activity. GPI
anchor-hydrolyzing activity was measured in assay
 .buffer containing 0.6 pmol AChE and 0.1% wrv
Triton X-100 in a total volume of 25 ml. After
incubation at 378C for 16 h, the product of the
reaction, i.e. soluble AChE, was separated from non-
hydrolyzed substrate by phase partitioning in Triton
X-114. AChE activity was measured according to
w xEllman et al. 30 . One unit of GPI-PLD activity is
defined as 1 pmol soluble AChE produced per min 1
pmol AChE corresponds to 0.43 IU AChE activity
w x.31 .
2.7. Immunofluorescence staining
After three days of incubation, cells were scraped,
resuspended in phosphate-buffered saline, spread on a
glass slide, and dried at room temperature overnight
at normal pressure, followed by 24 h under vacuum.
Cells were then washed three times with phosphate-
buffered saline, fixed for 10 min in acetone, and
washed again. For intracellular labeling, cells were
permeabilized for 5 min with phosphate-buffered
 .saline containing 0.1% wrv Triton X-100, and
washed as above. For cell surface labeling, this step
was left out. Subsequently, cells were saturated with
albumin by incubation for 5 min in phosphate-
 .buffered saline containing 3% wrv albumin, and
incubated 1 h at room temperature with mouse mono-
clonal antibody 117-1 in phosphate-buffered saline
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 .containing 3% wrv albumin. After removel of un-
bound antibody by extensive washing, cells were
incubated for 30 min with FITC-conjugated rabbit
anti-mouse immunoglobulin diluted 40-fold in phos-
phate-buffered saline containing 3% albumin. After
two washing steps with phosphate-buffered saline
containing 3% albumin and one with phosphate-
buffered saline, cells were covered with Mounting
 .Medium Sigma, Switzerland , and the coverslips
were added. The Mounting Medium was dried
overnight at room temperature, and the cells were
analyzed using a fluorescence microscope.
2.8. Protein iodination
Labeling of proteins by 125I was performed using
IODO-BEADS iodination reagent from Pierce Rock-
.ford, IL, USA . Two beads were washed for 5 min in
 .iodination buffer 0.2 M sodium phosphate, pH 7.2 ,
and dried on filter paper. Subsequently, the beads
were preincubated for 5 min with 1 mCi Na125I in
100 ml iodination buffer and the protein solution
 .500 ml was added and incubated for 10 min at
room temperature. Unreacted Na125I as well as 125I3
was separated from the labeled protein by chromatog-
raphy on Bio-Gel P-6 DG desalting gel 130"40
. mm in a Bio-Rad Econo-Column 0.7=18 cm bed
.volume .
2.9. SDS-PAGE and Western blotting
SDS-PAGE was performed under reducing condi-
 .tions in the presence of 5% vrv b-mercaptoethanol
w xaccording to Lammli 32 using 5–15% polyacryl-¨
amide gradient gels. Proteins were stained with
Coomassie brilliant blue R-250. Western blots were
carried out essentially as described by Hoener and
w xBrodbeck 15 . Prior to blotting, polyvinylidene diflu-
oride membranes were immersed for 10 min in
methanol, followed by 10 min in blotting buffer 10
 . .mM CAPS, pH 11.0, 10% vrv methanol . After
blotting, the membranes were saturated at room tem-
 .perature with 3% wrv albumin in Tris-buffered
saline for 3 h, and incubated overnight at 108C with
mouse monoclonal antibody 117-1 against GPI-PLD.
Subsequently, the membrane was washed twice with
 .Tris-buffered saline containing 0.05% vrv Tween
20, and incubated for 6 h at room temperature with
horseradish-peroxidase-conjugated goat anti-mouse
 .IgG Bio-Rad, Glattbrug, Switzerland diluted 1:750
in Tris-buffered saline. After two washes with Tris-
 .buffered saline containing 0.05% vrv Tween 20,
proteins were stained with a solution of 0.5 mgrml
 .diaminobenzidine and 0.5 mlrml 30% vrv H O .2 2
Polyacrylamide gels containing radiolabeled material
were dried and exposed on Kodak X-OMAT S dental
film, or analyzed using a Bio-Rad phosphor imager.
2.10. RNA extraction and Northern blotting
RNA was isolated using the guanisine-isothio-
cyanate-cesium chloride procedure as described by
w xMeese and Blin 33 . Messenger RNA was purified
using the Oligotex-dT kit from Qiagen Chatsworth,
.CA, USA . Complementary DNA construct, reverse
transcription PCR, agarose gel electrophoresis, and
Northern blotting was done exactly as described by
w xStadelmann et al. 34 .
2.11. Protein assay
Protein was determined in microtiter plates using
the BCA reagent kit Pierce Chemicals, Rockford, IL,
.USA with bovine serum albumin as standard.
3. Results
While mammalian cells contain no or only small
amounts of GPI-PLD, body fluids are relatively rich
w xin this activity 15 . Since the isolated enzyme has not
been shown to be active on membrane-bound GPI
substrates in vitro, it is possible that GPI-PLD hydro-
lyzes GPI structures only intracellularly, i.e. after
uptake from blood or other body fluids. In order to
study this hypothesis, GPI-PLD was purified from
bovine serum in quantities large enough to allow
uptake studies in N2A neuroblastoma cells. This cell
line was selected because we found that N2A cells
cultured in serum-free medium had no measurable
GPI-PLD activity although very low levels of GPI-
PLD mRNA were detected in this cell line results
.not shown .
3.1. Uptake of GPI-PLD by N2A cells
To study the uptake of GPI-PLD by N2A cells two
 .forms of the enzyme were prepared, i.e. i the native
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 .115 kDa form of GPI-PLD, and ii a proteolytically
processed form of GPI-PLD that was obtained after
w xtreatment of the intact enzyme with trypsin 27 . FCS
used for cell cultures contains high amounts of GPI-
 .PLD activity 35–40 Urml . In order to follow up-
take of GPI-PLD into N2A cells cultured in FCS-con-
taining medium using GPI-PLD activity measure-
ments, FCS was pre-treated by transiently raising the
pH to 11. This procedure resulted in complete )
.99% inhibition of serum-derived GPI-PLD activity.
Four days before the experiment, N2A cells were
shifted to culture medium containing GPI-PLD-in-
activated FCS. Immediately before the addition of
isolated GPI-PLD, the cells were shifted to a fully
synthetic cell culture medium that had no measurable
GPI-PLD activity. N2A cells were then incubated
with increasing amounts of purified GPI-PLD over a
period of 48 h, harvested, and cell-associated GPI-
PLD was assayed by enzyme activity measurement.
We found that within the concentration range tested,
GPI-PLD activity in N2A cells increased linearly
with increasing amounts of GPI-PLD added to the
 .cells Fig. 1A . After addition of a given amount of
GPI-PLD to N2A cells, cell-associated GPI-PLD ac-
tivity increased linearly with time over a period of 4
 .days at 378C Fig. 1B . Control cells incubated in the
absence of added enzyme showed little GPI-PLD
activity. No time-dependent increase in cell-associ-
ated GPI-PLD activity was observed when the cells
 .were incubated at 158C or 48C results not shown .
Unless otherwise noted, all subsequent experiments
were done using a GPI-PLD concentration of 1 Urml
medium.
In order to further confirm the presence of GPI-
PLD in N2A cells and to study a possible intra-
cellular processing of the enzyme after uptake, we
performed Western blot analyses using a monoclonal
anti-GPI-PLD antibody. This antibody recognizes the
intact 115 kDa form of GPI-PLD as well as prote-
olytic degradation products with molecular masses
w x)42 kDa 27 . Unfortunately, we were unable to
detect GPI-PLD in N2A cells, probably because the
amount of GPI-PLD in the cell pellet was below the
 .limit of detection of the antibody result not shown .
Similarly, we did not detect intracellular or cell sur-
face-bound GPI-PLD by immunofluorescence mi-
 .croscopy result not shown . In control experiments
to test the method of immunofluorescence staining,
Fig. 1. Uptake of GPI-PLD by N2A cells. A. Increasing amounts
of purified GPI-PLD were added to N2A cells in culture and
incubated for 48 h at 378C. Subsequently, the cells were scraped
from the tissue plates, washed thoroughly, and GPI-PLD activity
was measured in the cell pellets. The data points represent mean
values "S.D. of triplicate determinations from two parallel
 .experiments. B. Purified GPI-PLD 1 Urml final concentration
was added to N2A cells and incubated for 96 h at 378C. At given
timepoints, cells were harvested and GPI-PLD activity in the cell
pellets was measured as described in A. The data points represent
single determinations from two parallel incubations from a typi-
 .cal experiment carried out in the presence filled circles or
 .absence open circles of added GPI-PLD. For experimental
details see Section 2.
we were able to detect cell surface bound GPI-PLD
in COS-1 cells expressing GPI-PLD.
3.2. Radiolabeling of GPI-PLD and albumin
As an alternative way to verify the uptake of
GPI-PLD into N2A cells and to study a possible
intracellular processing of the enzyme, we prepared
radiolabeled GPI-PLD. Purified intact GPI-PLD Fig.
. 2, lane a and trypsin-treated GPI-PLD Fig. 2, lane
. 125b were radiolabeled with I, and the products were
analyzed by SDS-PAGE followed by autoradiog-
raphy. After radioiodination, intact GPI-PLD showed
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Fig. 2. SDS-PAGErautoradiography of unlabeled and labeled
forms of GPI-PLD. Purified GPI-PLD from bovine serum lanes
.  .a, c , trypsin-treated purified GPI-PLD lanes b, d , and bovine
 . 125serum albumin lane e were radioiodinated with I and ana-
lyzed by SDS-PAGE on 5–15% acrylamide gradient gels. Protein
 .was stained with Coomassie lanes a, b , and radiolabeled prod-
 .ucts were visualized by autoradiography lanes c, d, e . For
experimental details see Section 2. Mobilities of the commercial
molecular mass markers are indicated in the left margin. The
 .positions of intact GPI-PLD 115 kDa , bovine serum albumin
 . 66 kDa , and the two major trypsin fragments of GPI-PLD 39
.kDa and 33 kDa are indicated in the right margin.
 .a single band at 115 kDa Fig. 2, lane c , while the
trypsin-treated form showed two major polypeptides
 .at 39 kDa and 33 kDa Fig. 2, lane d . As a control
protein to use in the uptake studies, we also radioiod-
 .inated bovine serum albumin Fig. 2, lane e .
When radiolabeled intact GPI-PLD was added to
N2A cells in culture, we found that the amount of
radioactivity that associated with the cell pellet in-
 .creased over time Fig. 3A . Similarly, an increase in
cell-associated radioactivity was found when the la-
beled trypsin-treated form of GPI-PLD was added to
 .the cells Fig. 3B . A different uptake kinetic was
125  .found for I-labeled albumin Fig. 3C : A rapid
increase of cell-associated label was observed during
the first hours of incubation reaching equilibrium
 .after about 24 h Fig. 3C .
After incorporation, 125I-labeled protein was ana-
lyzed by SDS-PAGE followed by autoradiography.
As seen in Fig. 4, the intact 115 kDa form of
GPI-PLD was degraded. After one and four days of
incubation practically no more 115 kDa form of
GPI-PLD could be seen, but a number of proteolytic
fragments were detected between 101 kDa and 39
kDa as well as near the front of the gel Fig. 4, lanes
. 125a, b . The I-labeled trypsin-treated form of GPI-
PLD yielded the patterns shown in Fig. 4, lanes c and
d. The main bands were at 39 and 33 kDa and a
number of small peptides were seen near the front of
the gel. On the other hand, 125I-labeled albumin was
more rapidly and completely degraded to small pep-
tides migrating near the front of the gel without any
 .intermediates detectable Fig. 4, lanes e, f .
Fig. 3. Uptake of radiolabeled proteins by N2A cells. A total of
6 125  .2=10 cpm of I-labeled intact form of GPI-PLD panel A ,
125  .I-labeled trypsin-treated form of GPI-PLD panel B , and
125  .I-labeled albumin panel C , were added to N2A cells in
culture and incubated up to 48 h at 378C. Incubations in A and B
were done in the presence of 1 Urml unlabeled GPI-PLD to
mimick the conditions used in Fig. 1B. At given timepoints, cells
were harvested as described in Fig. 1, and cell-associated radioac-
tivity was measured. The data points represent single determina-
tions from two parallel incubations from a typical experiment.
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3.3. Incubation of N2A with GPI-PLD in the presence
of chloroquine
After endocytosis, extracellular macromolecules
are often directed via early and late endosomes to
lysosomes where they are proteolytically degraded
 w x.reviewed by Berg et al. 35 . The rapid and com-
plete degradation of 125I-labeled albumin to small
peptides is consistent with such a lysosomal transport
followed by degradation. On the other hand, GPI-PLD
was found to be only partially degraded. In order to
obtain information on the intracellular localization of
GPI-PLD after uptake by N2A cells, we studied
whether the degradation of radiolabeled GPI-PLD
could be affected by the presence of the lysosomal
agent, chloroquine. Chloroquine is a weak base that
is rapidly taken up into endocytic vesicles where it
w xaccumulates and raises the acidic pH 36 . As a
result, the proteases in these compartments become
w xinactivated 37,38 , and degradation in endosomes
and lysosomes is slowed down or inhibited. When
N2A cells were incubated for 24 h with intact 125I-
Fig. 4. SDS-PAGErautoradiography of cell-associated radiola-
beled products. N2A cells were incubated at 378C in the presence
125  . 125of I-labeled intact GPI-PLD lanes a, b or I-labeled
 .  .trypsin-treated form of GPI-PLD lanes c, d for 24 h lanes a, c
 . 125and 48 h lanes b, d . I-labeled albumin was incubated with
 .  .N2A cells for 30 min lane e and 48 h lane f . The cell pellets
were collected as described in Fig. 1, lyzed in buffer containing
protease inhibitors, and stored at y208C. Equal amounts of
protein per lane were applied on a 5–15% acrylamide gradient
gel and separated by SDS-PAGE under reducing conditions.
Radiolabeled bands were visualized by exposing the dried gel to
 . a phosphor immager lanes a, b , or by autoradiography lanes
.c–f . The margins are as described in Fig. 2.
Fig. 5. Effects of chloroquine on the degradation of 125I-labeled
proteins. N2A cells were incubated at 378C with 125I-labeled
 . 125intact GPI-PLD lanes a, b , I-labeled trypsin-treated form of
 . 125  .GPI-PLD lanes c, d , or with I-labeled albumin lanes e, f for
 .  .24 h in the absence lanes a, c, e or presence lanes b, d, f of
100 mM chloroquine. Cell-associated radioactivity was analyzed
by SDS-PAGErautoradiography as described in Fig. 4. The
margins are as described in Fig. 2.
labeled GPI-PLD in the absence and presence of 100
mM chloroquine, the patterns shown in Fig. 5, lanes a
and b, resulted. It is seen that chloroquine slowed
down the degradation of the 115 kDa form of GPI-
PLD and the formation of the low molecular mass
breakdown products migrating near the front of the
 .gel was significantly inhibited Fig. 5, lane a vs. b .
When N2A cells were incubated with trypsin-treated
GPI-PLD in the presence of choloquine, the 39 kDa
and 33 kDa forms were not further degraded Fig. 5,
. 125lane c vs. d . Also, the degradation of I-labeled
albumin in N2A cells was almost completely inhib-
ited by the presence of 100 mM chloroquine Fig. 5,
.lane e vs. f . It has been demonstrated that low
amounts of chloroquine only inhibit the recycling of
w xreceptors 39 . Consequently we tested the effect of
10 mM chloroquine on the uptake of GPI-PLD. Our
results showed that the uptake was not affected by
this low amount of chloroquine.
4. Discussion
Although GPI-PLD occurs in relatively large
amounts in mammalian serum, milk, and cere-
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w xbrospinal fluid 15 , no apparent function of the
enzyme has been reported in these body fluids. Puri-
fied GPI-PLD from serum has been shown to readily
act on detergent-solubilized GPI-anchored proteins,
but it is still unclear if the forms of GPI-PLD occur-
ring in body fluids are able to release GPI-anchored
proteins from intact cell membranes. There is, how-
ever, evidence that the enzyme may be active intra-
cellularly. In COS-1 cells co-transfected with GPI-
PLD and GPI-anchored placental alkaline phos-
phatase, the majority of alkaline phosphatase was
w xreleased into the cell culture supernatant 24 , indicat-
ing that GPI hydrolysis by GPI-PLD had occured in
an intracellular compartment. Similarly, a GPI-
anchored construct of rubella virus E1 glycoprotein
was secreted from COS-1 cells after co-expression
w xwith GPI-PLD 40 . In addition, the release of GPI-
anchored proteins from HeLa and bone marrow stro-
mal cells was reported to be the result of intracellular
GPI-PLD-mediated cleavage of protein GPI anchors
w x22 .
In serum several proteolytically processed and
catalytically active forms of GPI-PLD can be de-
w xtected in addition to the intact 115 kDa form 26 .
Proteolytic processing of GPI-PLD can be mimicked
in vitro by treatment of the 115 kDa enzyme with
trypsin resulting in the generation of two main frag-
w xments of 33 and 39 25,27 . The catalytic activity of
the processed form was shown to be 3 to 4-fold
w xhigher than that of the 115 kDa enzyme 25 . The
lack of activity of GPI-PLD from mammalian body
fluids towards membrane-bound substrates in vitro
together with the observation that GPI-PLD can be
activated by trypsin treatment, lead us to hypothesize
that GPI-PLD may become active intracellularly after
uptake into cells and proteolytic processing in an
intracellular compartment. We recently studied the
subcellular distribution of GPI-PLD in rat liver and
w xfound that the enzyme is enriched in lysosomes 28 .
We now demonstrate that purified GPI-PLD from
bovine serum can be taken up by the mouse neuro-
blastoma cell line N2A. The uptake was found to
occur in a concentration- and time-dependent way.
Our results suggest that the uptake of GPI-PLD by
N2A cells occurred by fluid phase pinocytosis, since
 .it i increased linearly with increasing concentrations
of GPI-PLD added to the cells, i.e. without signifi-
w x  .cant adsorption to the plasma membrane 41 , and ii
w xoccurred linearly over 48 h of incubation 42 . Our
findings that cell-associated GPI-PLD activity contin-
uously increased for more than 2 days indicated that
the enzyme was taken up by N2A cells faster than it
was inactivated by proteolytic events within the cells.
Moreover, GPI-PLD seemed to be retained by the
cells with little reflux to the cell culture supernatant.
Unfortunately we were not able to locate the enzyme
intracellularly by immunofluorescence staining
mainly because the amount of GPI-PLD taken up by
the cells was below the limit of detection by the
monoclonal antibody 117-1. Another possible reason
for the lack of detection of GPI-PLD after uptake into
N2A cells may relate to the fact that our antibody
only recognizes N-terminal fragments of GPI-PLD
w xwith molecular masses larger than 42 kDa 27 and
thus, would not detect proteolytically degraded GPI-
PLD fragments.
Our results using 125I-labeled GPI-PLD confirmed
the GPI-PLD uptake kinetic obtained by enzyme
activity measurements. In addition, the trypsin-treated
form of GPI-PLD showed a similar uptake into N2A
cells. It is of interest to note that the amount of
 125 .GPI-PLD both activity and I-labeled protein re-
covered in N2A cells increased with time and that no
steady state was reached even after 2 days of incuba-
tion. This result indicates that GPI-PLD must be
remarkably stable towards complete degradation by
lysosomal proteases. In contrast 125I-labeled albumin
taken up by N2A cells was rapidly and completely
degraded. Such a result is expected for a protein
w xhaving no function in lysosomes 35 . As seen from
the pattern of 125I-labeled GPI-PLD the intact 115
kDa form is processed to smaller peptides which
have also been detected in the enzyme isolated from
w xserum 26 . In transfected COS-1 cells several bands
of GPI-PLD with molecular masses between 115 and
47 kDa were detected by immunoblotting M. Kung,¨
P. Butikofer, U. Brodbeck and B. Stadelmann, un-¨
.published results which gives additional evidence
that GPI-PLD is proteolytically processed within the
cell. The finding that this process takes place with
retention of activity is consistent with earlier observa-
tions showing that the GPI-PLD fragments generated
w xby trypsin remained fully active 27 .
The fact that intracellular proteolytic degradation
of albumin was inhibited by the presence of chloro-
quine shows that the processing could be slowed
( )T. Hari et al.rBiochimica et Biophysica Acta 1355 1997 293–302 301
down by raising the pH of intracellular acidic com-
w xpartments such as endosomes and lysosomes 37,38 .
Since the presence of chloroquine also slowed down
the intracellular processing of GPI-PLD, it is reason-
able to assume that this process also took place in an
acidic compartment. This view is consistent with our
recent finding that in rat liver cells GPI-PLD is
w xlocalized in a lysosomal fraction 28 .
Taken together, our results show that GPI-PLD is
taken up from the medium into N2A cells where a
controlled proteolytic processing takes place in an
acidic intracellular compartment resulting in GPI-PLD
fragments of molecular masses between 101 and 39
kDa. The intracellular processing of GPI-PLD gener-
ates an active enzyme that may be involved in the
degradation of GPI-anchored structures in endosomes
or lysosomes.
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